Aesthetic laser co Syneron gains more from Candela acquisition

Candela obtained Japanese Ministry of Health approval for its Vbeam laser device for the treatment of vascular conditions.

Syneron Medical Ltd. (Nasdaq: ELOS) continues to reap rewards from its acquisition of US company Candela Corporation. The Yokne'am-based developer of aesthetic laser treatments yesterday announced that Candela obtained Japanese Ministry of Health, Labor and Welfare approval for the company's Vbeam long pulsed dye laser system in Japan for the treatment of vascular conditions. The Vbeam is the first and only long pulsed dye laser system approved for use in Japan.

Syneron completed the acquisition of Candela just under a year ago for $65 million in shares. Syneron made the acquisition to help minimize damage from the credit crisis, which severely affected its business in North America, and to enter new markets, such as Japan. Syneron, founded by chairman Shimon Eckhouse, has lost a tenth of value since the beginning of the year.

Syneron CEO Lou Scafuri said, "This marks a significant milestone in our global distribution as physicians and patients in Japan will now have full access to the gold standard treatments that Vbeam offers."

The importance of the Japanese approval, in addition to expanding Syneron's geographical scope, lies in the facilitation of insurance reimbursements to physicians and patients for treatments with the Vbeam for certain medical condition, which will expand patients' access to it. Given Japan's large population and prevalence of esthetic and vascular lesions, the approval result in a substantial source of future revenue for Syneron.

Syneron's share closed at $9.40 yesterday, giving a market cap of $320 million.

Published by Globes [online], Israel business news - www.globes-online.com - on July 21, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters